CAR T-cell adverse-event monitoring/management in MCL was reported suboptimal by 54%, peaking in Germany and Brazil community practices, whereas BTK inhibitor management gaps in MCL affected 30%.
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results